PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 223 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Nirogacestat Shows Significant Benefit in Patients with Progressing Desmoid Tumours March 20, 2023 Tennis Legend Chris Evert Says She’s Been Diagnosed with Ovarian Cancer January 18, 2022 Responding to Coronavirus, Cancer Researchers Reimagine Clinical Trials June 29, 2020 Dr Ian Walker on Smoking: ‘A political no-brainer’ March 24, 2023 Load more HOT NEWS Born Blind With 50% Chance Of Survival, 20-Year-Old Musician Defied All... A Novel Combination of Cabozantinib Plus Atezolizumab Demonstrates Encouraging Activity and... No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in... Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why
